The molecular biology of diffuse large B-cell lymphoma

Therapeutic Advances in Hematology

Volumn 2, Issue 6, 2011, Pages 369-379

  Frick, Mareike ^a   Dorken, Bernd ^a   Lenz, Georg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

biology; DLBCL; gene expression profiling; malignant lymphoma; molecular pathogenesis

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; SHORT HAIRPIN RNA;

B CELL LYMPHOMA; B LYMPHOCYTE DIFFERENTIATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MARGINAL ZONE LYMPHOMA; MOLECULAR PATHOLOGY; PREDICTION; PRIMARY MEDIASTINAL B CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84993731486     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620711419001     Document Type: Review

References (67)

1. Alizadeh A.A. Eisen M.B. Davis R.E. Ma C. Lossos I.S. Rosenwald A. et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503–511.
2. Bea S. Zettl A. Wright G. Salaverria I. Jehn P. Moreno V. et al. (2005) Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 106: 3183–3190.
3. Cerchietti L.C. Ghetu A.F. Zhu X. Da Silva G.F. Zhong S. Matthews M. et al. (2010) A small-molecule inhibitor of BCL 6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17: 400–411.
4. Cerchietti L.C. Lopes E.C. Yang S.N. Hatzi K. Bunting K.L. Tsikitas L.A. et al. (2009) A purine scaffold Hsp 90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 15: 1369–1376.
5. Chalhoub N. Baker S.J. (2009) PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4: 127–150.
6. Choi W.W. Weisenburger D.D. Greiner T.C. Piris M.A. Banham A.H. Delabie J. et al. (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15: 5494–5502.
7. Coiffier B. (2001) Diffuse large cell lymphoma. Curr Opin Oncol 13: 325–334.
8. Coiffier B. Lepage E. Briere J. Herbrecht R. Tilly H. Bouabdallah R. et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235–242.
9. Compagno M. Lim W.K. Grunn A. Nandula S.V. Brahmachary M. Shen Q. et al. (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459: 717–721.
10. Dave S.S. Fu K. Wright G.W. Lam L.T. Kluin P. Boerma E.J. et al. (2006) Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354: 2431–2442.
11. Davis R.E. Brown K.D. Siebenlist U. Staudt L.M. (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194: 1861–1874.
12. Davis R.E. Ngo V.N. Lenz G. Tolar P. Young R.M. Romesser P.B. et al. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463: 88–92.
13. de Jong D. Xie W. Rosenwald A. Chhanabhai M. Gaulard P. Klapper W. et al. (2009) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 62: 128–138.
14. Dunleavy K. Pittaluga S. Czuczman M.S. Dave S.S. Wright G. Grant N. et al. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 113: 6069–6076.
15. Ferch U. Kloo B. Gewies A. Pfander V. Duwel M. Peschel C. et al. (2009) Inhibition of MALT 1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 206: 2313–2320.
16. Friedberg J.W. Sharman J. Sweetenham J. Johnston P.B. Vose J.M. Lacasce A. et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578–2585.
17. Hailfinger S. Lenz G. Ngo V. Posvitz-Fejfar A. Rebeaud F. Guzzardi M. et al. (2009) Essential role of MALT 1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 106: 19946–19951.
18. Hans C.P. Weisenburger D.D. Greiner T.C. Gascoyne R.D. Delabie J. Ott G. et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275–282.
19. Haralambieva E. Adam P. Ventura R. Katzenberger T. Kalla J. Holler S. et al. (2006) Genetic rearrangement of FOXP 1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation. Leukemia 20: 1300–1303.
20. Hummel M. Bentink S. Berger H. Klapper W. Wessendorf S. Barth T.F. et al. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354: 2419–2430.
21. Iqbal J. Greiner T.C. Patel K. Dave B.J. Smith L. Ji J. et al. (2007) Distinctive patterns of BCL 6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21: 2332–2343.
22. Jost P.J. Ruland J. (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109: 2700–2707.
23. Kato M. Sanada M. Kato I. Sato Y. Takita J. Takeuchi K. et al. (2009) Frequent inactivation of A 20 in B-cell lymphomas. Nature 459: 712–716.
24. Kloo B. Nagel D. Pfeifer M. Grau M. Duwel M. Vincendeau M. et al. (2011) Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 108: 272–277.
25. Lam L.T. Davis R.E. Wright G. Rosenwald A. Hurt E.M., X., Y. et al. (2005) Small molecule inhibitors of IkB-kinase are selectively toxic for subgroups of diffuse large B cell lymphoma defined by gene expression profiling. Clin Cancer Res 11: 28–40.
26. Lam L.T. Wright G. Davis R.E. Lenz G. Farinha P. Dang L. et al. (2008) Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor pathways in subtypes of diffuse large B-cell lymphoma. Blood 111: 3701–3713.
27. Lenz G. Davis R.E. Ngo V.N. Lam L. George T.C. Wright G.W. et al. (2008 a) Oncogenic CARD 11 mutations in human diffuse large B cell lymphoma. Science 319: 1676–1679.
28. Lenz G. Wright G. Dave S.S. Xiao W. Powell J. Zhao H. et al. (2008 b) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359: 2313–2323.
29. Lenz G. Wright G.W. Emre N.C. Kohlhammer H. Dave S.S. Davis R.E. et al. (2008 c) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105: 13520–13525.
30. Lossos I.S. Alizadeh A.A. Eisen M.B. Chan W.C. Brown P.O. Botstein D. et al. (2000) Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci U S A 97: 10209–10213.
31. Lossos I.S. Czerwinski D.K. Alizadeh A.A. Wechser M.A. Tibshirani R. Botstein D. et al. (2004) Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350: 1828–1837.
32. Malumbres R. Chen J. Tibshirani R. Johnson N.A. Sehn L.H. Natkunam Y. et al. (2008) Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 111: 5509–5514.
33. Melzner I. Bucur A.J. Bruderlein S. Dorsch K. Hasel C. Barth T.F. et al. (2005) Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 105: 2535–2542.
34. Melzner I. Weniger M.A. Bucur A.J. Bruderlein S. Dorsch K. Hasel C. et al. (2006) Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int J Cancer 118: 1941–1944.
35. Mestre C. Rubio-Moscardo F. Rosenwald A. Climent J. Dyer M.J. Staudt L. et al. (2005) Homozygous deletion of SOCS 1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. Leukemia 19: 1082–1084.
36. Meyer P.N. Fu K. Greiner T.C. Smith L.M. Delabie J. Gascoyne R.D. et al. (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29: 200–207.
37. Monti S. Savage K.J. Kutok J.L. Feuerhake F. Kurtin P. Mihm M. et al. (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105: 1851–1861.
38. Naylor T.L. Tang H. Ratsch B.A. Enns A. Loo A. Chen L. et al. (2011) Protein kinase C inhibitor Sotrastaurin selectively inhibits the growth of CD79-mutant diffuse large B-cell lymphomas. Cancer Res, in press.
39. Ngo V.N. Davis R.E. Lamy L. Yu X. Zhao H. Lenz G. et al. (2006) A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441: 106–110.
40. Ngo V.N. Young R.M. Schmitz R. Jhavar S. Xiao W. Lim K.H. et al. (2011) Oncogenically active MYD 88 mutations in human lymphoma. Nature 470: 115–119.
41. Nie K. Zhang T. Allawi H. Gomez M. Liu Y. Chadburn A. et al. (2010) Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol 177: 1470–1479.
42. Oltersdorf T. Elmore S.W. Shoemaker A.R. Armstrong R.C. Augeri D.J. Belli B.A. et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677–681.
43. Pasqualucci L. Compagno M. Houldsworth J. Monti S. Grunn A. Nandula S.V. et al. (2006) Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 203: 311–317.
44. Rawlings D.J. Sommer K. Moreno-Garcia M.E. (2006) The CARMA 1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 6: 799–812.
45. Rimsza L.M. Wright G.W. Schwartz M. Chan W. Jaffe E. Gascoyne R.D. et al. (2011) Classification of diffuse large B cell lymphoma into germinal center and activated B cell subtypes using a nuclease protection assay on paraffin embedded tissues. Clin Cancer Res, in press.
46. Ritz O. Guiter C. Dorsch K. Dusanter-Fourt I. Wegener S. Jouault H. et al. (2008) STAT 6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma. Leukemia 22: 2106–2110.
47. Rosenwald A. Wright G. Chan W.C. Connors J.M. Campo E. Fisher R.I. et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937–1947.
48. Rosenwald A. Wright G. Leroy K. Yu X. Gaulard P. Gascoyne R.D. et al. (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198: 851–862.
49. Rui L. Emre N.C. Kruhlak M.J. Chung H.J. Steidl C. Slack G. et al. (2010) Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell 18: 590–605.
50. Salmena L. Carracedo A. Pandolfi P.P. (2008) Tenets of PTEN tumor suppression. Cell 133: 403–414.
51. Savage K.J. Monti S. Kutok J.L. Cattoretti G. Neuberg D. de Leval L. et al. (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102: 3871–3879.
52. Schmidlin H. Diehl S.A. Nagasawa M. Scheeren F.A. Schotte R. Uittenbogaart C.H. et al. (2008) Spi-B inhibits human plasma cell differentiation by repressing BLIMP 1 and XBP-1 expression. Blood 112: 1804–1812.
53. Schmitz R. Hansmann M.L. Bohle V. Martin-Subero J.I. Hartmann S. Mechtersheimer G. et al. (2009) TNFAIP 3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 206: 981–989.
54. Shaffer A.L. Lin K.I. Kuo T.C. Yu X. Hurt E.M. Rosenwald A. et al. (2002) Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17: 51–62.
55. Shaffer A.L. Shapiro-Shelef M. Iwakoshi N.N. Lee A.-H. Qian S.-B. Zhao H. et al. (2004) XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21: 81–93.
56. Shaffer A.L. Yu X. He Y. Boldrick J. Chan E.P. Staudt L.M. (2000) BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13: 199–212.
57. Streubel B. Vinatzer U. Lamprecht A. Raderer M. Chott A. (2005) T(3;14)(p14.1;q32) involving IGH and FOXP 1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19: 652–658.
58. Tagawa H. Suguro M. Tsuzuki S. Matsuo K. Karnan S. Ohshima K. et al. (2005) Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106: 1770–1777.
59. Tam W. Gomez M. Chadburn A. Lee J.W. Chan W.C. Knowles D.M. (2006) Mutational analysis of PRDM 1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 107: 4090–4100.
60. Tunyaplin C. Shaffer A.L. Angelin-Duclos C.D. Yu X. Staudt L.M. Calame K.L. (2004) Direct repression of prdm 1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol 173: 1158–1165.
61. Uddin S. Hussain A.R. Siraj A.K. Manogaran P.S. Al-Jomah N.A. Moorji A. et al. (2006) Role of phosphatidylinositol 3’-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 108: 4178–4186.
62. van Besien K. Kelta M. Bahaguna P. (2001) Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 19: 1855–1864.
63. Weniger M.A. Melzner I. Menz C.K. Wegener S. Bucur A.J. Dorsch K. et al. (2006) Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25: 2679–2684.
64. Williams P.M. Li R. Johnson N.A. Wright G. Heath J.D. Gascoyne R.D. (2010) A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays. J Mol Diagn 12: 680–686.
65. Wilson W.H. O'Connor O.A. Czuczman M.S. La Casce A.S. Gerecitano J.F. Leonard J.P. et al. (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11: 1149–1159.
66. Wright G. Tan B. Rosenwald A. Hurt E.H. Wiestner A. Staudt L.M. (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 100: 9991–9996.
67. Xiao C. Srinivasan L. Calado D.P. Patterson H.C. Zhang B. Wang J. et al. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol 9: 405–414.